Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03749863 · ClinicalTrials.gov registry record · NA

Serial Platelet-Rich Plasma Injections for Vocal Fold Atrophy, Scar, and/or Sulcus Vocalis

A NA study of Dysphonia and Presbylarynx, sponsored by University of Southern California.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT03749863: Completed NA study of Dysphonia and Presbylarynx, sponsored by University of Southern California.

NCT03749863 is a NA study of Dysphonia and Presbylarynx that has completed, run by University of Southern California. The registered enrollment target is 14 participants, below the 60-participant average among 7 other Dysphonia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03749863, a NA study of Dysphonia and Presbylarynx, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This study will investigate the safety and efficacy of four serial monthly vocal fold injections of platelet-rich plasma to treat dysphonia secondary to vocal fold atrophy, scar, and/or sulcus vocalis with glottal insufficiency

Primary Outcome

Adverse event severity grading scale from 1 to 4, with grade 1 as mild, grade 2 as moderate, grade 3 as severe, and grade 4 potentially life-threatening

Interventions

  • PROCEDURE Serial PRP injections

Study Locations (1)

California

  • University of Southern California - Los Angeles

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2020-02-18
Est. Completion 2022-09-30
Phase NA
University of Southern California

617 total trials

What the finished NCT03749863 record still lists

NCT03749863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 7 other Dysphonia trials with a reported enrollment target (77% lower).

The record links to 7 conditions, with Dysphonia appearing as the primary indexed condition, and to 1 intervention - of which Serial PRP injections is the first listed.

NCT03749863 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03749863 about?

NCT03749863 is a clinical study titled "Serial Platelet-Rich Plasma Injections for Vocal Fold Atrophy, Scar, and/or Sulcus Vocalis". This study will investigate the safety and efficacy of four serial monthly vocal fold injections of platelet-rich plasma to treat dysphonia secondary to vocal fold atrophy, scar, and/or sulcus vocalis with glottal insufficiency

What is the current status of trial NCT03749863?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2020-02-18. Estimated completion is 2022-09-30.

What conditions does trial NCT03749863 study?

This clinical trial studies the following conditions: Dysphonia, Presbylarynx, Atrophy; Larynx, Vocal Cord Atrophy, Presbylarynges.

What interventions are being tested in trial NCT03749863?

The interventions under investigation include: Serial PRP injections (PROCEDURE).

Who is sponsoring clinical trial NCT03749863?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03749863 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dysphonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03749863, the US trial registry maintained by the National Library of Medicine. NCT03749863 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.